COMMITTED TO INNOVATION After more than eighty years of activity the Angelantoni group ranks among the leading companies in the testing sector and has a unique offer with regard to renewable energy, particularly solar. Industry Europe speaks to Mr Margherita and Mr Scarponi - respectively General Manager and COO of its ATT divisionMr Cagiola -General Manager of ASE- and Ms Manni - R&D Engineer for the Cold Energy project (ACT division). Barbara Rossi reports.
A
ngelantoni was established in 1932 by 28 year-old Giuseppe Angelantoni as a refrigeration business. Over the years the business has grown and diversified and in 2012 a new organisational structure was created. Today Angelantoni Industrie is a group with three sub-holdings and one subsidiary. The three sub-holdings are Angelantoni Test Technologies (ATT), Angelantoni Life Science (ALS) and Angelantoni CleanTech (ACT), while the subsidiary is Archimede Solar Energy (ASE). While having Italian roots and being headquartered in the Perugia area of central Italy, the group has a truly international mindset, with eight production plants in Italy, Germany, France, India and China. Angelantoni
is characterised by a high level of innovation in the testing (ATT), biomedical (ALS), and clean technologies (ACT) sectors, as well as in the solar sector (ACT and ASE). ATT really stands out for its wide and comprehensive range of testing solutions, which are offered through its three brands: ACS (environmental test chambers), BIA (automotive and aerospace test benches) and TIRA (electrodynamic vibration test systems, material testing equipment, balancing machines and mechanical engineering). Research and collaboration with universities and research institutes feature highly and have resulted in various patents and extremely innovative products. ALS a is leader in the manufacture of biomedical equipment and medical devices
for healthcare and pharmaceutical sectors, as well for life science research Institutes. Besides a complete range of cold storage, laminar flow and infection control equipment, ALS offers to major hospitals and industries in the world a new generation of solutions which include software and robotic automation operating at extremely low temperature, setting a new standard in patient safety and traceability of biological samples in life science processes. It invests 10 per cent of its revenue in R&D, which has led to several international patents for unique products in Bloodbanking and Biobanking fields, like Hemosafe® and Smartfreezer®, the only available fully automated system to store and retrieve individual biological samples at cryogenic temperature (Liquid
